Gaudium IVF Women Health IPO Listing at 5.06% Premium at ₹83 Per Share

Posted by : Ekta Dhawan | Fri Feb 27 2026

Gaudium IVF Women Health IPO Listing Today: The Gaudium IVF & Women Health IPO was subscribed 7.27 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 1.62 times, and non-institutional investors (NIIs) received 1.62 times. The retail quota of the issue was subscribed to 35.00%. Before delving deeper into the topic, go through the details of the Gaudium IVF & Women Health IPO.

Table of Contents

Gaudium IVF Women Health IPO

It is a bookbuilding IPO of ₹165.00 crore, comprising an entirely fresh issue of 1.14 crore shares and an offer-for-sale of 0.95 crore shares. The issue will be listed on BSE and NSE on its tentative listing date, 27th February 2026. The Gaudium IVF & Women Health IPO date is fixed between 20th February 2026 and 24th February 2026. The face value of Gaudium IVF & Women Health shares stands at ₹10 per share, and the IPO Issue price band is set at ₹75 to ₹79 per share

IPO Allotment Date	25th February 2026
IPO Open Date	20th January 2026
IPO Close Date	24th February 2026
Refund Initiation	25th February 2026
Issue Size	2,08,86,200 shares(agg. up to ₹165 Cr)
Fresh Issue	1,13,92,500 shares(agg. up to ₹90 Cr)
Offer for Sale	94,93,700 shares of ₹5(agg. up to ₹75 Cr)
Face Value	₹5 per share
Lot Size	189 Shares
Issue Price	₹75 to ₹79 per share
Issue Type	Bookbuilding IPO
Listing At	BSE NSE
Listing Date	27th February 2026

Gaudium IVF & Women Health Listing

On the BSE & NSE platforms, Gaudium IVF & Women Health shares are listed at ₹83 per share, reflecting a 5.06% Premium over the issue price of ₹79 per share.

About Gaudium IVF & Women Health Limited

Gaudium IVF & Women Health Incorporated in March 2015, Gaudium IVF and Women Health Limited have been involved in In Vitro Fertilisation (IVF) procedures across India and have extended their services to several states using a hub-and-spoke model of operation. The firm has more than thirty locations, consisting of seven hubs (centres) and twenty-eight spokes. The firm has formed a strategic alliance with Infertility Experts, referred to as Spokes, to attain the common goal of creating awareness about Assisted Reproductive Technology (ART) and In Vitro Fertilisation (IVF) procedures. The firm provides services to patients belonging to different nations, such as Canada, the United Kingdom, the United States of America, Kenya, South Africa, and Oman.

Gaudium IVF & Women Health Limited Financials

The company’s financial analysis is essential before applying for the Gaudium IVF & Women Health IPO. See the table for Gaudium IVF & Women Health Limited’s financials.

Year Ended	30th Sep 2025 (in cr.)	31st March 2025 (in cr.)	31st March 2024 (in cr.)	31st March 2023 (in cr.)
Assets	106.62	88.51	51.01	36.63
Revenue	49.75	70.96	48.15	44.26
Profit After Tax	12.51	19.13	10.32	13.53
EBITDA	18.95	28.63	19.27	20.07
Net Worth	58.85	46.30	26.99	22.73
Reserves and Surplus	28.16	15.60	26.00	21.74
Total Borrowings	22.51	18.93	15.73	9.78

Explanation

Gaudium IVF & Women Health Limited’s revenue increased by 47.37% from ₹48.15 crores in March 2024 to ₹70.96 crores in March 2025. Moreover, the company’s PAT increased by 85.36% from ₹10.32 crores in March 2024 to ₹19.13 crores in March 2025.